Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci

被引:47
作者
He, YX
Honnen, WJ
Krachmarov, CP
Burkhart, M
Kayman, SC
Corvalan, J
Pinter, A
机构
[1] Publ Hlth Res Inst, Lab Retroviral Biol, Newark, NJ 07103 USA
[2] Abgenix Inc, Fremont, CA 94555 USA
关键词
D O I
10.4049/jimmunol.169.1.595
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Despite considerable interest in the isolation of mAbs with potent neutralization activity against primary HIV-1 isolates, both for identifying useful targets for vaccine development and for the development of therapeutically useful reagents against HIV-1 infection, a relatively limited number of such reagents have been isolated to date. Human mAbs (hu-mAbs) are preferable to rodent mAbs for treatment of humans, but isolation of hu-mAbs from HIV-infected subjects by standard methods of EBV transformation of B cells or phage display of Ig libraries is inefficient and limited by the inability to control or define the original immunogen. An alternative approach for the isolation of hu-mAbs has been provided by the development of transgenic mice that produce fully hu-mAbs. In this report, we show that immunizing the XenoMouse G2 strain with native recombinant gp120 derived from HIVSF162 resulted in robust Immoral Ab responses against gp120 and allowed the efficient isolation of hybridomas producing specific hu-mAbs directed against multiple regions and epitopes of gp120. hu-mAbs possessing strong neutralizing activity against the autologous HIVSF162 strain were obtained. The epitopes recognized were located in three previously described neutralization domains, the V2-, V3- and CD4-binding domains, and in a novel neutralization domain, the highly variable C-terminal region of the V1 loop. This is the first report of neutralizing mAbs directed at targets in the VI region. Furthermore, the V2 and V3 epitopes recognized by neutralizing hu-mAbs were distinct from those of previously described human and rodent mAbs and included an epitope requiring a full length V3 loop peptide for effective presentation. These results further our understanding of neutralization targets for primary, R5 HIV-1 viruses and demonstrate the utility of the XenoMouse system for identifying new and interesting epitopes on HIV-1.
引用
收藏
页码:595 / 605
页数:11
相关论文
共 73 条
[1]   Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease [J].
Berger, EA ;
Murphy, PM ;
Farber, JM .
ANNUAL REVIEW OF IMMUNOLOGY, 1999, 17 :657-700
[2]   Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers [J].
Berman, PW ;
Gray, AM ;
Wrin, T ;
Vennari, JC ;
Eastman, DJ ;
Nakamura, GR ;
Francis, DP ;
Gorse, G ;
Schwartz, DH .
JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (02) :384-397
[3]   A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure [J].
Binley, JM ;
Sanders, RW ;
Clas, B ;
Schuelke, N ;
Master, A ;
Guo, Y ;
Kajumo, F ;
Anselma, DJ ;
Maddon, PJ ;
Olson, WC ;
Moore, JP .
JOURNAL OF VIROLOGY, 2000, 74 (02) :627-643
[4]   HIV vaccines - Viral envelope fails to deliver? [J].
Bolognesi, DP ;
Matthews, TJ .
NATURE, 1998, 391 (6668) :638-639
[5]   EFFICIENT NEUTRALIZATION OF PRIMARY ISOLATES OF HIV-1 BY A RECOMBINANT HUMAN MONOCLONAL-ANTIBODY [J].
BURTON, DR ;
PYATI, J ;
KODURI, R ;
SHARP, SJ ;
THORNTON, GB ;
PARREN, PWHI ;
SAWYER, LSW ;
HENDRY, RM ;
DUNLOP, N ;
NARA, PL ;
LAMACCHIA, M ;
GARRATTY, E ;
STIEHM, ER ;
BRYSON, YJ ;
CAO, YZ ;
MOORE, JP ;
HO, DD ;
BARBAS, CF .
SCIENCE, 1994, 266 (5187) :1024-1027
[6]   A LARGE ARRAY OF HUMAN MONOCLONAL-ANTIBODIES TO TYPE-1 HUMAN-IMMUNODEFICIENCY-VIRUS FROM COMBINATORIAL LIBRARIES OF ASYMPTOMATIC SEROPOSITIVE INDIVIDUALS [J].
BURTON, DR ;
BARBAS, CF ;
PERSSON, MAA ;
KOENIG, S ;
CHANOCK, RM ;
LERNER, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (22) :10134-10137
[7]   VIROLOGICAL AND IMMUNOLOGICAL CHARACTERIZATION OF LONG-TERM SURVIVORS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION [J].
CAO, YZ ;
QIN, LM ;
ZHANG, LQ ;
SAFRIT, J ;
HO, DD .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (04) :201-208
[8]   DISTINCT MODES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROVIRAL LATENCY REVEALED BY SUPERINFECTION OF NONPRODUCTIVELY INFECTED CELL-LINES WITH RECOMBINANT LUCIFERASE-ENCODING VIRUSES [J].
CHEN, BK ;
SAKSELA, K ;
ANDINO, R ;
BALTIMORE, D .
JOURNAL OF VIROLOGY, 1994, 68 (02) :654-660
[9]   ISOLATES OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 FROM THE BRAIN MAY CONSTITUTE A SPECIAL GROUP OF THE AIDS VIRUS [J].
CHENGMAYER, C ;
WEISS, C ;
SETO, D ;
LEVY, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (21) :8575-8579
[10]   DNA vaccination with the human immunodeficiency virus type 1 SF162ΔV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8+ T-cell-depleted rhesus macaques [J].
Cherpelis, S ;
Shrivastava, I ;
Gettie, A ;
Jin, X ;
Ho, DD ;
Barnett, SW ;
Stamatatos, L .
JOURNAL OF VIROLOGY, 2001, 75 (03) :1547-1550